Get in Touch
English
- English
- French
- German
- Portuguese
- Spanish
- Russian
- Japanese
- Korean
- Arabic
- Irish
- Greek
- Turkish
- Italian
- Danish
- Romanian
- Indonesian
- Czech
- Afrikaans
- Swedish
- Polish
- Basque
- Catalan
- Esperanto
- Hindi
- Lao
- Albanian
- Amharic
- Armenian
- Azerbaijani
- Belarusian
- Bengali
- Bosnian
- Bulgarian
- Cebuano
- Chichewa
- Corsican
- Croatian
- Dutch
- Estonian
- Filipino
- Finnish
- Frisian
- Galician
- Georgian
- Gujarati
- Haitian
- Hausa
- Hawaiian
- Hebrew
- Hmong
- Hungarian
- Icelandic
- Igbo
- Javanese
- Kannada
- Kazakh
- Khmer
- Kurdish
- Kyrgyz
- Latin
- Latvian
- Lithuanian
- Lithuanian
- Macedonian
- Malagasy
- Malay
- Malayalam
- Maltese
- Maori
- Marathi
- Mongolian
- Burmese
- Nepali
- Norwegian
- Pashto
- Persian
- Punjabi
- Serbian
- Sesotho
- Sinhala
- Slovak
- Slovenian
- Somali
- Samoan
- Scots Gaelic
- Shona
- Sindhi
- Sundanese
- Swahili
- Tajik
- Tamil
- Telugu
- Thai
- Ukrainian
- Urdu
- Uzbek
- Vietnamese
- Welsh
- Xhosa
- Yiddish
- Yoruba
- Zulu
- Kinyarwanda
- Tatar
- Oriya
- Turkmen
- Uyghur
News
2025-05-30 |Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that works similarly to an immunotherapy from Akeso and Summit Therapeutics.
Pfizer buys into PD-1/VEGF competition with 3SBio deal
2025-05-30 |The advisory committee said vaccine makers should tailor their booster doses to the “JN.1” coronavirus lineage. The FDA doesn’t have to follow their advice, but usually does.
FDA panel recommends keeping COVID shots targeted to same strain as last year
2025-05-30 |The biotech will use the cash to fund human testing of a drug it believes to have potential against several autoimmune conditions.
GlycoEra raises $130M, riding interest in protein degraders
2025-05-29 |Vaccines using mRNA technology have been studied for decades, experts say.
What we know about the safety, efficacy of mRNA vaccines amid recent scrutiny
